Accessibility Menu
LeonaBio logo

LeonaBio

(NASDAQ) ATHA

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-96%
5 Year-92%
1 Year+84%
1 Month-12%
LeonaBio last closing stock price
MetricPriceDate
Last closeUSD 7.222026-07-17
LeonaBio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-24.79%USD 9.602026-07-10
1 month-12.27%USD 8.232026-06-17
3 month-18.51%USD 8.862026-04-17
Year to date-4.62%USD 7.572025-12-31
1 year+83.72%USD 3.932025-07-17
3 year-76.33%USD 30.502023-07-18
5 year-92.42%USD 95.202021-07-16
Since inception-95.78%USD 171.102020-09-18

LeonaBio Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$129.41M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 13, 2025

ATHA News

Foolcom-Featured.png

Athira (ATHA) Q2 Loss Narrows 74%

Motley Fool Markets TeamAug 7, 2025
two scientists discuss data in laboratory

Why Athira Pharma Stock Imploded Today

Alex CarchidiJun 22, 2022
GettyImages-633708215

Why Shares of Athira Pharma Are Climbing Today

Jason HawthorneOct 22, 2021
gettyimages-89938824-2048x2048

Why Athira Pharma Crashed Today

Eric VolkmanJun 18, 2021
GettyImages-680412758

Why Athira Pharma Stock Dropped Today

Prosper Junior BakinyJan 21, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About LeonaBio

LeonaBio develops medicines for people with serious brain and cancer diseases. Its drugs aim to slow disease and improve daily life. The company focuses on patients with few treatment options.

Lab Bench to Bedside: What LeonaBio Makes

  • Small molecule drugs: Experimental medicines for brain and cancer diseases; 0% of revenue (no sales).
  • Lasofoxifene: Oral drug in late-stage trials for advanced breast cancer with specific gene changes.
  • ATH-1105: Drug in early trials for amyotrophic lateral sclerosis (ALS), a severe nerve disease.
  • ATH-1020: Early-stage drug for nerve pain and other brain disorders.
  • Preclinical compounds: Additional drugs in laboratory testing for neurological diseases.

Growth Spurts and Strategic Moves

  • Acquired global rights (outside Asia/Middle East) to lasofoxifene in December 2025 from Sermonix.
  • Raised $90 million in private placement financing in December 2025 to fund new drug development.
  • Reduced workforce by 70% in September 2024 to cut costs and extend funding.
  • Shifted focus to late-stage breast cancer and ALS drug programs in 2025.
  • Uses third-party manufacturers for drug production, supporting flexible scaling.

What Makes LeonaBio Stand Out

LeonaBio targets diseases with few treatment options, focusing on drugs that reach the brain. It licenses late-stage assets to speed up development. The company relies on outside partners for manufacturing and holds patents extending into the 2040s.

Five Things You Need to Know

  • No product revenue in 2023, 2024, or 2025; all drugs are in development.
  • Net loss was $105.6 million in 2025, up 9% from 2024.
  • R&D expenses rose 21% to $85.6 million in 2025, driven by new drug rights.
  • Cash used in operations improved to $45.7 million in 2025, down from $97.2 million in 2024.
  • Cash and investments totaled $88.3 million at December 31, 2025.

Bottom Line

LeonaBio has shifted its focus to late-stage cancer and brain disease drugs. The company remains pre-commercial, relying on external funding and partnerships to advance its pipeline.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

19

CEO

Mark J. Litton, PhD, MBA

Website

www.leonabio.com

Headquarters

Bothell, WA 98011, US

ATHA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-381.01%

Return on Capital

-357.66%

Return on Assets

-180.77%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$67.85M

Operating Income

-$109.94M

EBITDA

-$7.52M

Operating Cash Flow

-$51.97M

Capital Expenditure

$0.00

Free Cash Flow

-$51.97M

Cash & ST Invst.

$67.68M

Total Debt

$691.00K

LeonaBio Performance Analysis

LeonaBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
LeonaBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
LeonaBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -25.3570.6%
20232023-12-31USD -30.9522.1%
20242024-12-31USD -25.19-18.6%
20252025-12-31USD -24.70-2.0%
LeonaBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.6%
Q32025-09-305.6%
Q42025-12-31-1027.4%
Q12026-03-3190.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

26

N/A

Net Income

-$32.95M

-260.4%

EBITDA

-$17.21M

-93.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$67.68M

+84.6%

Total Debt

$691.00K

-38.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$213.00K

-69.2%

Short Term Debt

$478.00K

+12.2%

Return on Assets

-1.81%

N/A

Return on Invested Capital

-1.71%

N/A

Free Cash Flow

-$20.90M

-42.5%

Operating Cash Flow

-$20.90M

-42.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LPTXLeap Therapeutics, Inc.
$0.77-3.15%
CTXRCitius Pharmaceuticals, Inc.
$0.50-2.88%
ICUSeaStar Medical Holding Corporation
$4.00-5.21%
APLMApollomics, Inc.
$18.52-20.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NFLXNetflix
$68.95-0.07%
INTCIntel
$95.04-0.02%

Questions About ATHA

What is the current price of LeonaBio?

LeonaBio is trading at N/A per share.

What is the 52-week range for LeonaBio?

Over the past 52 weeks, LeonaBio has traded between N/A and N/A.

How much debt does LeonaBio have?

As of the most recent reporting period, LeonaBio reported total debt of $691.00K.

How much cash does LeonaBio have on hand?

LeonaBio reported $32.83M in cash and cash equivalents in its most recent financial results.

What is LeonaBio’s dividend yield?

LeonaBio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services